NASDAQ$MLTX
MoonLake Immunotherapeutics · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
MLTX Q4 2023 — $350.0M revenue, 0.73 EPS
Annual Report on Form 10-K, including without limitation, statements regarding the following, are forward-looking statements: our future results of operations and financial position, our expectations . MoonLake Immunotherapeutics reported Q4 2023 results. Diluted EPS came in at $0.73. Net income of $44.1M. Headline numbers extracted from the Form 10-K/A press release; narrative is light because this row was processed without an LLM call.
- Revenue: $350.0M.
- Diluted EPS: $0.73.
- Net income: $44.1M.
- Operating income: $54.1M.
Headline financials
Revenue & EPS history
MoonLake · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2023
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.7%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+23.1%
Q2 2022
Best reaction
-10.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.2% | -2.9% | -4.8% | |
| Q3 2025 | -2.8% | +11.0% | +40.7% | |
| Q1 2025 | +4.7% | -2.2% | +14.8% | |
| Q4 2024 | -4.5% | -2.5% | -2.1% | |
| Q3 2024 | +0.6% | +0.8% | +5.5% | |
| Q1 2024 | -4.2% | -8.1% | -4.7% | |
| Q4 2023 | -10.4% | -15.3% | -11.6% | |
| Q3 2023 | +7.1% | +16.6% | +57.3% | |
| Q2 2023 | +3.5% | +3.8% | -5.7% | |
| Q1 2023 | +0.2% | +5.5% | +9.6% | |
| Q4 2022 | -4.9% | -9.2% | -5.6% | |
| Q3 2022 | -0.1% | -5.4% | +4.0% | |
| Q2 2022 | +23.1% | +45.8% | +33.0% | |
| Q1 2022 | -6.1% | +4.3% | +2.6% | |
| Q2 2021 | -0.1% | +0.0% | -0.1% | |
| Q4 2021 | -0.1% | +0.0% | -0.1% | |
| Q3 2021 | -1.3% | -1.3% | -1.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro